Cipla LtdNSE: CIPLA

Press Release Aug 20 2020

· Issued by Cipla Ltd

Filed with NSE · · 4 pages · English

Summary by 6ix AI

This product is the first approved allogeneic cell therapy globally for this condition and aims to provide affordable treatment options for patients in India. Cipla will market and distribute Stempeucel® in India, leveraging its extensive distribution network.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Ltd on 6ix

Earlier from Cipla

Later from Cipla

All Cipla news releases